0001213900-24-075327.txt : 20240904 0001213900-24-075327.hdr.sgml : 20240904 20240904081002 ACCESSION NUMBER: 0001213900-24-075327 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240904 FILED AS OF DATE: 20240904 DATE AS OF CHANGE: 20240904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LakeShore Biopharma Co., Ltd. CENTRAL INDEX KEY: 0001946399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41598 FILM NUMBER: 241275931 BUSINESS ADDRESS: STREET 1: BUILDING NO. 2, 38 YONGDA ROAD STREET 2: DAXING BIOMEDICAL INDUSTRY PARK CITY: DAXING DISTRICT, BEIJING STATE: F4 ZIP: 102629 BUSINESS PHONE: 17327133678 MAIL ADDRESS: STREET 1: BUILDING NO. 2, 38 YONGDA ROAD STREET 2: DAXING BIOMEDICAL INDUSTRY PARK CITY: DAXING DISTRICT, BEIJING STATE: F4 ZIP: 102629 FORMER COMPANY: FORMER CONFORMED NAME: YS Biopharma Co., Ltd. DATE OF NAME CHANGE: 20230310 FORMER COMPANY: FORMER CONFORMED NAME: YishengBio Co., Ltd DATE OF NAME CHANGE: 20220912 6-K 1 ea0213427-6k_lakeshore.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2024

 

Commission file number: 001-41598

 

 

 

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

 

 

 

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒                   Form 40-F ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

LakeShore Biopharma Co., Ltd (the “Registrant”) is filing this Form 6-K to furnish a press release issued on September 4, 2024, announcing its leadership transitions, which is furnished herewith as Exhibit 99.1.

 

Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-279544 and File No. 333-273165) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBITS

 

Exhibit No.   Description
99.1   Press Release – LakeShore Biopharma Announces Leadership Transitions

 

2

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  LakeShore Biopharma Co., Ltd
   
  By: /s/ Rachel Yu
  Name: Rachel Yu
  Title: Director and Chief Financial Officer

 

Date: September 4, 2024

 

3

 

 EX-99.1 2 ea021342701ex99-1_lakeshore.htm PRESS RELEASE - LAKESHORE BIOPHARMA ANNOUNCES LEADERSHIP TRANSITIONS

Exhibit 99.1

 

LakeShore Biopharma Announces Leadership Transitions

 

GAITHERSBURG, Md., September 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the board of directors of the Company (the “Board”) has appointed Mr. Xu Wang as the Chief Executive Officer of the Company. He succeeds Mr. Dave Chenn and Dr. Hui Shao, who step down from the Company’s Interim Chief Executive Officer and Co-Chief Executive Officer position, respectively. Mr. Xu Wang has served as the Company’s Chief Operation Officer since June 2024, and he will no longer assume such role upon becoming the Chief Executive Officer of the Company.

 

The Board has also approved the appointment of Dr. Hui Shao as the Chief Business Officer of the Company, responsible for global strategic planning and global transactions, and the transition of Ms. Rachel Yu from the role of Interim Chief Financial Officer to Chief Financial Officer of the Company. Ms. Yu is also a partner at Oceanpine Capital’s healthcare practice since December 2021, where she is responsible for formulating the overall investment strategies in the healthcare sector and taking principal leadership responsibility in post-investment management of portfolio companies.

 

In addition to these leadership transitions, the Company also announced the appointment of Dr. Hui Shao as the Vice Chairman of the Board, and the appointment of Mr. Xu Wang as a new member of the Board. The leadership transitions and board appointments became effective on September 1, 2024.

 

About LakeShore Biopharma

 

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.lakeshorebio.com.

 

Investor Relations Contact

 

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com